R. van Kampen

Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?

M. de Boer, V. Tjan-Heijnen, V. Tjan-Heijnen, 2015, British Journal of Cancer.

Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome

M. de Boer, G. Borm, V. Tjan-Heijnen, 2013, Breast Cancer Research and Treatment.

Functional status decline in older patients with breast and colorectal cancer after cancer treatment: A prospective cohort study.

F. Buntinx, M. de Boer, V. Tjan-Heijnen, 2017, Journal of geriatric oncology.

Real-Life Use and Effectiveness of Adjuvant Trastuzumab in Early Breast Cancer Patients: A Study of the Southeast Netherlands Breast Cancer Consortium.

M. de Boer, V. Tjan-Heijnen, M. Joore, 2015, The oncologist.

Quality of life in a real-world cohort of advanced breast cancer patients: a study of the SONABRE Registry

M. de Boer, V. Tjan-Heijnen, M. Joore, 2020, Quality of Life Research.

Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium.

M. de Boer, V. Tjan-Heijnen, M. Joore, 2016, The oncologist.

The role of histological subtype in hormone receptor positive metastatic breast cancer: similar survival but different therapeutic approaches

V. Tjan-Heijnen, G. Vreugdenhil, N. Peters, 2016, Oncotarget.